# Data Sheet (Cat.No.T63751)

TargetMol

## Selvigaltin

### Chemical Properties



CAS No. : 1978336-95-6

Formula: C19H16BrF3N4O4S

Molecular Weight: 533.32

Storage: Keep away from direct sunlight,Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Selvigaltin (GB1211) is an orally administered, highly selective small-molecule inhibitor of galectin-3 (Gal-3) with an $IC_{50}$ value of 12 nM in rabbits, exhibiting anticancer and anti-fibrotic activity. Selvigaltin reduces galectin-3 levels in the liver and decreases biomarkers of inflammation (cellular foci) and fibrosis (PSR, SHG), while simultaneously lowering the mRNA and protein expression of inflammatory and fibrotic biomarkers (IL-6, TGF-β3, SNAI2, collagen). Selvigaltin also restores T-cell activity and reduces tumor growth and metastasis. Selvigaltin is suitable for use in studies of liver fibrosis, non-alcoholic steatohepatitis (NASH), and tumors. |
| Targets(IC50) | Neuropeptide Y Receptor,Galectin |
| In vivo | **Methods**: Male New Zealand White rabbits were fed a high-fat diet (standard diet + 0.5% cholesterol + 2.5% vegetable oil) for 12 weeks. From week 9 to week 12 of HFD feeding, oral administration (0.3-30 mg/kg) was performed once daily (5 days per week) for 4 consecutive weeks.<br>**Results**: Selvigaltin treatment significantly reduced galectin-3 protein and mRNA levels in the liver, confirming target binding.[1] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 265 mg/mL (496.89 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+90% Corn Oil: 1 mg/mL (1.88 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.875 mL | 9.3752 mL | 18.7505 mL |
| 5 mM | 0.375 mL | 1.875 mL | 3.7501 mL |
| 10 mM | 0.1875 mL | 0.9375 mL | 1.875 mL |
| 50 mM | 0.0375 mL | 0.1875 mL | 0.375 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Comeglio P, et al. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Front Pharmacol. 2024 Jul 31;15:1430109.
Lurje I, et al. The Role of Galectin-3 in Liver Inflammation and Fibrosis. J Inflamm Res. 2026;19:572637. Published 2026 Jan 8.
Slack RJ, et al. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021 Jan; 130:105881.
Aslanis V, et al. Single-Dose Pharmacokinetics and Safety of the Oral Galectin-3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clin Drug Investig. 2024 Oct 2.